Real World Evidence for Rare disease
Rare disease Day, recognises the 6,000+ identified, often life threatening, rare diseases*. Affecting over 300,000 million people worldwide, 72% of rare diseases are genetic, with 70% of those starting in childhood*. The low prevalence and…
Modelling our Values
Quarterly Recognition Awards At Prospection we believe that our values drive our behaviours and they’re what make all of us stand out from the crowd. This week we celebrated the incredible contributions from our whole…
Real World Data: Relevance and Value
Prospection integrate and analyse a range of data that includes administrative claims data, electronic medical records, hospital and insurance data and other big data sets. The integration and analysis of this data provides real world…
Machine Learning to Improve the Patient Journey
Machine learning and artificial intelligence tools (ML/AI) rapidly detect patterns the human eye can’t easily see. Analyse large patient datasets to understand and predict patterns to improve health outcomes. Pharma data insights using real world…
Values Award Recipients
Recognition Awards Winners At Prospection we believe that our values drive our behaviours and they’re what make all of us at Prospection stand out from the crowd. Congratulations to all of our winners and thank…
Moving Towards Precision Medicine
Advances in medical innovation are leading toward precision medicine, matching disease to targeted treatment. Data modelling using advanced technology has become important to support this development. Prospection Labs is where experimental and innovative ideas come…
Understanding the Treatment Journey using Real World Data
PharmDash is a real-world evidence platform that delivers insights into the use, value, and outcomes of different medications across all disease areas. Initially designed to work with the Australian Pharmaceutical Benefits Scheme (PBS) longitudinal patient…
Prospection launches in Japan
Today, we announce the opening of our Japan headquarters. With the appointment of health informatics and pharmaceutical veteran Kaoru Sato to lead our Japan operations. The new office in Tokyo will enable Prospection to work closely with international pharmaceutical and research partners. Offering the full suite of our health data science capabilities.
PharmMap, Geospatial Mapping in Healthcare
PharmMap provides geospatial data insights through integration of multiple health datasets. Purpose built to assist life science companies, PharmMap is a prominent tool within the Prospection product portfolio. It integrates operational and longitudinal health data…
Our Founders Vision for Healthcare Data Analytics
Prospection has developed into a company that clients can trust to help them achieve success. Our advanced knowledge and expertise in healthcare data analytics supports complex research questions. The experience and expertise of the 3 founders Eric, Ricky and Peter have contributed highly towards the rapid growth and success of Prospection
Prospection vision and values: A look into the future with CEO Eric Chung
Prospection is a health data analytics company that is currently based in Sydney. In the beginning Prospection started with just 3 people, its founders Eric, Ricky and Peter. 8 years on Prospection has thrived, growing…
Lessons from the Pandemic
The global COVID-19 pandemic brings into sharp focus how timely access to linked datasets supports more efficient decision making. Australia was lauded for its management of the global health challenge with so few lives lost….
Long-term persistence with single-pill, fixed-dose combination therapy versus two pills of amlodipine and perindopril for hypertension: Australian experience
To study treatment persistence and mortality using a single-pill, fixed-dose combination
tablet compared with a two-pill combination for hypertension.
Treatment persistence of subcutaneous TNF inhibitors among Australian patients with immune-mediated rheumatic disease (IMRD)
Introduction: To describe the persistence of treatment with subcutaneous tumor necrosis factor inhibitors (TNFi) adalimumab, etanercept, and golimumab in immune-mediated rheumatic dis-
ease (rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis) by treatment sequence (first-line treatment, second-line or further lines of treatment).
Patterns of Antipsychotic Medication Prescribing in Australia.
Schizophrenia is a mental health disorder characterised by hallucinations, delusions and disorganised behaviour. The Australian pharmaceutical benefits scheme (PBS) reimburse a number of antipsychotic therapies, however, there is little known around the patterns of utilisation and the patient characteristics of these options. Objective: To describe the antipsychotic treatment patterns and the time to antipsychotic switch.